Publications
Articles
Bourouh, M., Kim, J., & Marignani, P. A. (2026). Tumour suppressors LKB1 and SMARCA4 functionally interact to regulate gene expression of diverse biological processes in lung cancer. Frontiers in Cell and Developmental Biology 14:1685342. https://doi.org/10.3389/fcell.2026.1685342
Huo, B., Kontouli, K. M., Manos, D., Xu, Z., Chun, S., Fris, J., Wallace, A. M. R., & French, D. G. (2025). Screening Criteria Evaluation for Expansion in Pulmonary Neoplasias (SCREEN) II. Canadian journal of surgery. Journal canadien de chirurgie, 68(1), E1–E9. https://doi.org/10.1503/cjs.015223
Pathak, G., Shah, R., Castonguay, M., Cheng, A., Fris, J., Murphy, R., … & Xu, Z. (2024). Temporal effect on pd‐l1 detection and novel insights into its clinical implications in non–small cell lung cancer. Cancer Medicine, 13(19). https://doi.org/10.1002/cam4.70262
Hyrcza, M. D., Martins-Filho, S. N., Spatz, A., Wang, H., Purgina, B. M., Desmeules, P., Park, P. C., Bigras, G., Jung, S., Cutz, J., Xu, Z., Berman, D. M., Sheffield, B. S., Cheung, C. C., Leduc, C., Hwang, D. M., Ionescu, D., Klonowski, P., Chevarie-Davis, M., . . . Torlakovic, E. (2023). Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study. Modern Pathology, 37(1), 100384. https://doi.org/10.1016/j.modpat.2023.100384
Suraweera, T. L., Merlin, J. P. J., Dellaire, G., Xu, Z., & Rupasinghe, H. P. V. (2023). Genistein and Procyanidin B2 Reduce Carcinogen-Induced Reactive Oxygen Species and DNA Damage through the Activation of Nrf2/ARE Cell Signaling in Bronchial Epithelial Cells In Vitro. International Journal of Molecular Sciences, 24(4), 3676. https://doi.org/10.3390/ijms24043676
Huo, B., Manos, D., Xu, Z., Matheson, K., Chun, S., Fris, J., Wallace, A. M., & French, D. G. (2022). Screening criteria Evaluation for Expansion in Pulmonary Neoplasias (SCREEN). Seminars in Thoracic and Cardiovascular Surgery, 35(4), 769–780. https://doi.org/10.1053/j.semtcvs.2022.06.018
Ionescu, D. N., Stockley, T. L., Banerji, S., Couture, C., Mather, C. A., Xu, Z., Blais, N., Cheema, P. K., Chu, Q. S., Melosky, B., & Leighl, N. B. (2022). Consensus recommendations to optimize testing for new targetable alterations in Non-Small cell lung Cancer. Current Oncology, 29(7), 4981–4997. https://doi.org/10.3390/curroncol29070396
Chung, C. B., Lee, J., Barritault, M., Bringuier, P., Xu, Z., Huang, W., Beharry, A., Castillo, J., Christiansen, J., Lin, J. C., & Sheffield, B. S. (2021). Evaluating targeted Next-Generation sequencing assays and reference materials for NTRK fusion detection. Journal of Molecular Diagnostics, 24(1), 18–32. https://doi.org/10.1016/j.jmoldx.2021.09.008
Kim, J., Xu, Z., & Marignani, P. A. (2021). Single-cell RNA sequencing for the identification of early-stage lung cancer biomarkers from circulating blood. Npj Genomic Medicine, 6(1). https://doi.org/10.1038/s41525-021-00248-y
Cheung, C. C., Smith, A. C., Albadine, R., Bigras, G., Bojarski, A., Couture, C., Cutz, J., Huang, W., Ionescu, D., Itani, D., Izevbaye, I., Karsan, A., Kelly, M. M., Knoll, J., Kwan, K., Nasr, M. R., Qing, G., Rashid-Kolvear, F., Sekhon, H. S., . . . Tsao, M. (2021). Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer. Lung Cancer, 160, 127–135. https://doi.org/10.1016/j.lungcan.2021.08.003
Alwithenani, A., Bethune, D., Castonguay, M., Drucker, A., Flowerdew, G., Forsythe, M., French, D., Fris, J., Greer, W., Henteleff, H., MacNeil, M., Marignani, P., Morzycki, W., Plourde, M., Snow, S., Marcato, P., & Xu, Z. (2021). Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR. PLoS ONE, 16(5), e0251080. https://doi.org/10.1371/journal.pone.0251080
Rodriguez, T., Manos, D., Xu, Z., & Houston, S. (2021). Diffuse pulmonary ossification diagnosed by transbronchial biopsy: A case report. Canadian Journal of Respiratory Critical Care and Sleep Medicine, 6(3), 205–208. https://doi.org/10.1080/24745332.2021.1895007
Shah, R., Alex, D., & Xu, Z. (2021). MET Exon 14 Skipping Alterations in Non-small cell Lung Carcinoma—Current understanding and Therapeutic Advances. touchREVIEWS in Oncology & Haematology, 16(2), 100. https://doi.org/10.17925/ohr.2021.16.2.100
Suraweera, T. L., Rupasinghe, H. P. V., Dellaire, G., & Xu, Z. (2020). Regulation of NRF2/ARE Pathway by Dietary flavonoids: a friend or foe for cancer management? Antioxidants, 9(10), 973. https://doi.org/10.3390/antiox9100973
Forsythe, M. L., Alwithenani, A., Bethune, D., Castonguay, M., Drucker, A., Flowerdew, G., French, D., Fris, J., Greer, W., Henteleff, H., MacNeil, M., Marignani, P., Morzycki, W., Plourde, M., Snow, S., & Xu, Z. (2020). Molecular profiling of non-small cell lung cancer. PLoS ONE, 15(8), e0236580. https://doi.org/10.1371/journal.pone.0236580
Torlakovic, E., Albadine, R., Bigras, G., Boag, A., Bojarski, A., Cabanero, M., Camilleri-Broët, S., Cheung, C., Couture, C., Craddock, K. J., Cutz, J., Dhamanaskar, P., Fiset, P. O., Hossain, M., Hwang, D. M., Ionescu, D., Itani, D., Kelly, M. M., Kwan, K., . . . Tsao, M. S. (2020). Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC. Journal of Thoracic Oncology, 15(8), 1328–1337. https://doi.org/10.1016/j.jtho.2020.03.029
Enfield, K. S. S., Marshall, E. A., Anderson, C., Ng, K. W., Rahmati, S., Xu, Z., Fuller, M., Milne, K., Lu, D., Shi, R., Rowbotham, D. A., Becker-Santos, D. D., Johnson, F. D., English, J. C., MacAulay, C. E., Lam, S., Lockwood, W. W., Chari, R., Karsan, A., . . . Lam, W. L. (2019). Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma. Nature Communications, 10(1). https://doi.org/10.1038/s41467-019-13295-y
Cheung, C. C., Barnes, P., Bigras, G., Boerner, S., Butany, J., Calabrese, F., Couture, C., Deschenes, J., El-Zimaity, H., Fischer, G., Fiset, P. O., Garratt, J., Geldenhuys, L., Gilks, C. B., Ilie, M., Ionescu, D., Lim, H. J., Manning, L., Mansoor, A., . . . Torlakovic, E. E. (2019). Fit-For-Purpose PD-L1 biomarker Testing for patient selection in Immuno-Oncology: Guidelines for clinical laboratories from the Canadian Association of Pathologists-Association Canadienne des Pathologistes (CAP-ACP). Applied Immunohistochemistry & Molecular Morphology, 27(10), 699–714. https://doi.org/10.1097/pai.0000000000000800
Torlakovic, E., Lim, H. J., Adam, J., Barnes, P., Bigras, G., Chan, A. W., Cheung, C. C., Chung, J., Couture, C., Fiset, P. O., Fujimoto, D., Han, G., Hirsch, F. R., Ilie, M., Ionescu, D., Li, C., Munari, E., Okuda, K., Ratcliffe, M. J., . . . Tsao, M. (2019). “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Modern Pathology, 33(1), 4–17. https://doi.org/10.1038/s41379-019-0327-4
Bebb, D. G., Agulnik, J., Albadine, R., Banerji, S., Bigras, G., Butts, C., Couture, C., Cutz, J. C., Desmeules, P., Ionescu, D. N., Leighl, N. B., Melosky, B., Morzycki, W., Rashid-Kolvear, F., Lab, C., Sekhon, H. S., Smith, A. C., Stockley, T. L., Torlakovic, E., . . . Tsao, M. S. (2019). Crizotinib inhibition of ROS1-Positive tumours in Advanced Non-Small-Cell lung Cancer: a Canadian perspective. Current Oncology, 26(4), 551–557. https://doi.org/10.3747/co.26.5137
Martinez, V. D., Marshall, E. A., Anderson, C., Ng, K. W., Minatel, B. C., Sage, A. P., Enfield, K. S. S., Xu, Z., & Lam, W. L. (2019). Discovery of previously undetected MicroRNAs in mesothelioma and their use as Tissue-of-Origin markers. American Journal of Respiratory Cell and Molecular Biology, 61(2), 266–268. https://doi.org/10.1165/rcmb.2018-0204le
Pathak, G. P., Shah, R., Kennedy, B. E., Murphy, J. P., Clements, D., Konda, P., Giacomantonio, M., Xu, Z., Schlaepfer, I. R., & Gujar, S. (2018). RTN4 knockdown dysregulates the AKT pathway, destabilizes the cytoskeleton, and enhances Paclitaxel-Induced cytotoxicity in cancers. Molecular Therapy, 26(8), 2019–2033. https://doi.org/10.1016/j.ymthe.2018.05.026
Zhao, Y., Castonguay, M., Wilke, D., Xu, Z., Plourde, M., Mulroy, L., MacNeil, M., & Bowes, D. (2018). Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma. Current Problems in Cancer, 43(1), 54–65. https://doi.org/10.1016/j.currproblcancer.2018.05.006
Corkery, D. P., Clarke, L. E., Gebremeskel, S., Salsman, J., Pinder, J., Page, C. L., Meunier, L., Xu, Z., Mes-Masson, A., Berman, J. N., Johnston, B., & Dellaire, G. (2017). Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking. Oncogene, 37(2), 174–184. https://doi.org/10.1038/onc.2017.318
Singh, R. K., Gallant, J. W., Greer, W., Xu, Z., & Douglas, S. E. (2017). An unbalanced Exon-Expression QPCR-based assay for detection of ALK translocation (Fusion) in lung cancer. Pulmonary Research and Respiratory Medicine - Open Journal, 4(1), 9–18. https://doi.org/10.17140/prrmoj-4-132
Williams, A. S., Greer, W., Bethune, D., Craddock, K. J., Flowerdew, G., & Xu, Z. (2016). ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization. Virchows Archiv, 469(5), 533–540. https://doi.org/10.1007/s00428-016-2005-y
Sabri, A., Batool, M., Xu, Z., Bethune, D., Abdolell, M., & Manos, D. (2016). Predicting EGFR mutation status in lung cancer:Proposal for a scoring model using imaging and demographic characteristics. European Radiology, 26(11), 4141–4147. https://doi.org/10.1007/s00330-016-4252-3
Xu, Z. (2015). Significance of molecular genotyping for lung cancer in modern oncology. Pulmonary Research and Respiratory Medicine - Open Journal, 2(3), 120–121. https://doi.org/10.17140/prrmoj-2-119
Greer, W., Douglas, S., Xu, Z., Morzycki, W., MacNei, M., Stone, A., & Drew Bethune, D. (2015). Molecular diagnostics for lung cancer in Atlantic Canada. Canadian Journal of Pathology, 7(1), 20–26.
Singh, R. K., Bethune, D. C., Xu, Z., & Douglas, S. E. (2015). Role of MicroRNAs in progression and recurrence of Early-Stage lung adenocarcinoma. Pulmonary Research and Respiratory Medicine - Open Journal, 2(1), 52–62. https://doi.org/10.17140/prrmoj-2-108
Douglas, S. E., Bethune, D. C., & Xu, Z. (2014). Microarray analysis identifies pathways in progression of early stage lung adenocarcinoma: the importance of focal adhesion and ECM-Receptor interactions. Pulmonary Research and Respiratory Medicine - Open Journal, 1(1), 21–31. https://doi.org/10.17140/prrmoj-1-104
Cutz, J., Craddock, K. J., Torlakovic, E., Brandao, G., Carter, R. F., Bigras, G., Deschenes, J., Izevbaye, I., Xu, Z., Greer, W., Yatabe, Y., Ionescu, D., Karsan, A., Jung, S., Fraser, R. S., Blumenkrantz, M., Lavoie, J., Fortin, F., Bojarski, A., . . . Tsao, M. (2014). Canadian Anaplastic Lymphoma Kinase Study: A model for Multicenter Standardization and Optimization of ALK testing in lung Cancer. Journal of Thoracic Oncology, 9(9), 1255–1263. https://doi.org/10.1097/jto.0000000000000239
Andrade-Vieira, R., Xu, Z., Colp, P., & Marignani, P. A. (2013). Loss of lkb1 Expression Reduces the Latency of ErbB2-Mediated Mammary Gland Tumorigenesis, Promoting Changes in Metabolic Pathways. PLoS ONE, 8(2), e56567. https://doi.org/10.1371/journal.pone.0056567
Book Chapters
Xu Z. and Camilleri-Broët S. Pulmonary Pathology in Pathology Review (3nd ed) ed. Zu-Hua Gao, Brush Educarion Inc. 2021
Xu Z. Pulmonary Pathology in Pathology Review (2nd ed) ed. Zu-Hua Gao, Brush Educarion Inc. 2017
Xu Z. Genomics and Molecular Profiling of Lung Cancer in Cancer Genomics: from bench to personalized medicine eds. G. Dellaire, J. Berman, R. Arceci. Academic Press, Elsevier, 2014
Xu Z and Urbanski S. Pulmonary Pathology in Pathology Review ed. Zu-Hua Gao, Brush Education Inc. 2013